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management of symptomatic carotid disease expanded the
indications for carotid artery stenting (CAS), advising that CAS
is now an alternative to carotid endarterectomy (CEA) in the
treatment of “average risk” patients suffering a transient
ischaemic attack (TIA) or minor stroke during the preceding 6
months.1 This recommendation was based on a review of
outcomes from contemporary randomised controlled trials
(RCTs), most notably the Carotid Revascularization Endarter-
ectomy versus Stenting Trial (CREST),2 along with evidence
from industry sponsored CAS registries.
The decision to expand CAS indications into average risk
symptomatic patients infuriated many surgeons, who were
otherwise convinced that this was only possible through the
inclusion of peri-operative myocardial infarction (MI) within a
composite primary endpoint of 30 day death/stroke/MI. As far
as they were concerned, a meta-analysis of pooled European
RCT data had clearly shown that CAS was associated with a
signiﬁcantly higher risk of procedural death/stroke
(CAS ¼ 8.9% vs 5.8% after CEA, HR 1.53, 95% CI 1.20e1.95;
p ¼ .0006).1 Moreover (and not withstanding North American
criticisms about interventionist experience and poor outcomes
in the European trials), had the traditional “30 day death/
stroke” endpoint been retained by the AHA, CREST would also
have shown signiﬁcant beneﬁt favouring CEA in recently
symptomatic patients (30 day death/stroke after CAS ¼ 6.0%
vs 3.0% after CEA, HR 1.89, 95% CI 1.11e3.21; p ¼ .019).
Interestingly, in each of the constituent studies, the difference
in procedural risk was most marked in older patients and was
mainly driven by a higher prevalence of non-disabling stroke.3
Following this opening salvo (which led to conﬂicting
guideline recommendations around the world),1,4 many sur-
geons probably thought that the war would ultimately be won
following publication of late outcome data. Intuitively, sur-
geons believed that in addition to higher peri-operative risks,
CAS would also be handicapped with signiﬁcantly higher rates
of restenosis and, consequently, signiﬁcantly higher rates of
late ipsilateral stroke. Only time would tell.
That time is now upon us and a series of late results from
the various RCTs make for interesting reading. The Stent-
Protected Angioplasty versus Carotid Endarterectomy
(SPACE) study surprised the surgical community with a 2008
report showing that while a recurrent stenosis of 70% was
signiﬁcantly more common at 2 years after CAS (11.1% CAS vs
4.6% CEA; p ¼ .0007), only two patients with a signiﬁcant
recurrent stenosis developed recurrent ipsilateral symptoms.5
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which showed that severe restenosis/occlusion was rare, with
no differences being observed between CAS and CEA. In
addition, a meta-analysis of older randomised trials also
showed no signiﬁcant increase in rates of severe restenosis
after primary stenting compared with CEA.6
Having shown that higher rates of restenosis did not seem
to matter, each of the major RCTs has now published late
clinical data. Provided any strokes occurring within the ﬁrst 30
days were excluded, there did not seem to be any difference in
the long-term risk of late stroke between CAS and CEA. ICSS is
now the latest (and largest RCT in symptomatic patients) to
publish long-term data, which in some patients extends out to
10 years.7 Consistent with previously published ﬁndings from
CREST, the Carotid And Vertebral Artery Transluminal Angio-
plasty Study (CAVATAS), the Stenting and Angioplasty with
Protection in Patients at High Risk for Endarterectomy (SAP-
PHIRE), SPACE, and EVA-3S, ICSS has reported that (after
excluding peri-operative stroke) the 5 year risk of fatal and/or
disabling stroke in patients randomised to CAS was very
similar to CEA (3.4% after CAS vs. 4.3% after CEA, HR 0.93, 95%
CI 0.53e1.60; p ¼ .78). There was also no signiﬁcant difference
in the 5 year rate of ipsilateral stroke (4.7% after CAS vs. 3.4%
after CEA, HR 1.29, 95% CI 0.74e2.24; p ¼ .36). The key
message, therefore, is that six large RCTs have now shown
that, after the ﬁrst 30 days have elapsed, the long-term risk of
stroke appears to be virtually the same for both CAS and CEA,
and that this appears to be a consistent and statistically robust
observation.
Accordingly, the single most important factor in deter-
mining whether patients should preferably undergo CAS (as
opposed to CEA) remains the magnitude of the initial proce-
dural risk. Put simply, if the procedural risk after CAS can be
reduced, it is inevitable that CAS will assume an ever
increasing role in everyday clinical practice. Such a reduction
might be achieved through better patient selection, the use of
simulators, inexperienced interventionists avoiding more
challenging cases, and the evolution of better CAS technolo-
gies (protection devices, stents, delivery catheters).8
However, although it is an indisputable fact that CAS and its
associated technologies have advanced considerably over the
last decade, there are several “elephants in the room” that
must be addressed before CAS can assume a more general-
isable role for the majority of symptomatic patients, and by
the majority of practitioners. The ﬁrst relates to developing
strategies for overcoming the substantial learning curve
associated with CAS (which may require up to 2 years of
experience in a high volume centre9,10), while the second re-
lates to the perennial issue of how CAS can establish a gen-
eralisable and safe role in a world where recently symptomatic
patients are now treated as soon as possible after the onset of
272 Editorialsymptoms. Neither of these key issues were addressed in the
latest AHA guidelines, but the drive towards treating symp-
tomatic patients as soon as possible after the onset of
symptoms has considerable ramiﬁcations for expanding the
role of CAS in otherwise “average risk” symptomatic patients.
The reason for this change in practice is a growing awareness
that the highest risk time period for suffering a stroke after the
index event is the ﬁrst few days, with overviews of natural
history studies suggesting that the risk of stroke may reach
20% at 7 days.11 This has led many guideline groups to
recommend that carotid interventions be performed within 14
days, whereas some advocate 48 hours.12 This move towards
expedited interventions therefore, poses a considerable chal-
lenge to CAS practitioners, especially as a recent meta-analysis
suggests that CAS is associated with a threefold excess risk of
procedural stroke if performed within 7 days of the index
symptom (compared with CEA) and a twofold excess risk when
performed between 8 and 14 days.13 The high procedural
stroke risk after CAS (when performed early) is almost
certainly secondary to increased rates of intra-procedural
embolisation (despite the use of embolic protection devices),
because of the higher prevalence of surface thrombus when
interventions are undertaken shortly after the index event.
More subtly (but of similar importance), surface thrombus and
increased intra-procedural embolisation will also have been
responsible for the signiﬁcantly higher rates of new MR-DWI
lesions seen after CAS (compared with CEA), which have
now been shown to be associated with a higher risk of
suffering late neurological events.14 It remains to be seen
whether proximal protection devices can reduce the preva-
lence of stroke and new DWI lesion when CAS is performed in
the hyperacute period after the onset of symptoms.
In conclusion, CAS has witnessed major advances in tech-
nology and safety over the last two decades and an important
milestone has now been reached in that all of the major RCTs
have shown that CAS appears to be as durable as CEA,
following the ﬁrst 30 days. Notwithstanding the important
issue of patient preference however, the magnitude of the
initial procedural risk will continue to dictate whether CAS or
CEA is safer. CREST-2, ACT-1, and ACST-2 will provide valuable
information in asymptomatic patients, but the key challenge
for CAS practitioners will now be to demonstrate that CAS can
be performed safely in the ﬁrst 7e14 days after onset of
symptoms with procedural risks comparable with CEA.
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